Leerink Partners Maintains OP Following Diplomat Pharmacy (DPLO) Q1
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/13/2026
- Wall Street ends higher as SpaceX's market debut dominates
- SpaceX prices historic IPO at $135/share in largest ever new listing
- 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
- UBS cuts gold price forecasts on delayed Fed easing outlook
- Brent falls to lowest since March on expected peace deal
- NASDAQ adds five companies to NASDAQ-100 index in quarterly rebalance
- Super Micro Computer establishes $1.25 billion stock sale agreement
- Wall Street ends higher as SpaceX's market debut dominates
- 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
- SpaceX Shares Indicated To Open At $155
Diplomat Announces 1st Quarter Financial Results
May 11, 2015 4:07 PM EDTFLINT, Mich., May 11, 2015 /PRNewswire/ -- Diplomat Pharmacy, Inc. (NYSE: DPLO), the nation's largest independent specialty pharmacy, announced financial results for the quarter ended March 31, 2015. All comparisons, unless otherwise noted, are to the quarter ended March 31, 2014.
First Quarter 2015 Highlights include:
Revenue of $625 million, an increase of 34% Total prescriptions dispensed of 194,000, an increase of 6% Gross margin of 6.6% versus 6.3% Adjusted EBITDA of $11.2 million, an increase of 36% Adjusted EPS of $0.09, versus $0.05... More